Repros Therapeutics Inc.® (Nasdaq: RPRX) today reported results from a large, controlled, long-term safety study comparing Androxal® to a placebo ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE